KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $165.0 million.

  • Edwards Lifesciences' Accounts Payables fell 451.39% to $165.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.0 million, marking a year-over-year decrease of 451.39%. This contributed to the annual value of $197.4 million for FY2024, which is 578.78% up from last year.
  • As of Q3 2025, Edwards Lifesciences' Accounts Payables stood at $165.0 million, which was down 451.39% from $162.1 million recorded in Q2 2025.
  • In the past 5 years, Edwards Lifesciences' Accounts Payables registered a high of $861.1 million during Q2 2021, and its lowest value of $139.5 million during Q3 2021.
  • Its 5-year average for Accounts Payables is $246.0 million, with a median of $185.9 million in 2024.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 8303.13% in 2021, then skyrocketed by 2304.71% in 2023.
  • Over the past 5 years, Edwards Lifesciences' Accounts Payables (Quarter) stood at $204.5 million in 2021, then fell by 1.27% to $201.9 million in 2022, then fell by 7.58% to $186.6 million in 2023, then grew by 5.79% to $197.4 million in 2024, then dropped by 16.41% to $165.0 million in 2025.
  • Its last three reported values are $165.0 million in Q3 2025, $162.1 million for Q2 2025, and $172.4 million during Q1 2025.